Kornimate/medical-research-clean huggingface dataset:
real-time observation of microcirculatory hemodynamics in gastric intestinal metaplasia by confocal laser endomicroscopy

Conditions: Flow Determination

Summary: the morphologic change of microvessels has the clinical value to distinguish cancerous from non-cancerous mucosa. the aim of this study was to observe gastric mucosa microcirculatory hemodynamic changes real-time using pcle, compare the differences between chronic nonatrophic gastritis and gim; then evaluate the possible mechanisms associated with gastric mucosal blood flow in gim.

consecutive patients with gim under endoscopic surveillance or examination at qilu hospital from march 1 to september 31, 2015 were recruited into this study. before the endomicroscopic examination, 20,000 u α-chymotrypsin and 80 mg dimethylpolysiloxane were given orally to remove gastric mucus. all patients were given intravenous injections of 1 ml of 2% fluorescein sodium (baiyunshan mingxing pharmaceutical, guangzhou, china) as an allergy test before procedures were carried out. conscious sedation was achieved for each patient by using propofol and fentanyl, and vital signs were monitored during the entire procedure. after successful intubation of the endoscope into the gastric antrum, 1 ml fluorescein sodium solution was applied intravenously as a contrast dye. the cle procedure did not differ from that of conventional colonoscopy, except for the additional storage of pcle images and videos in the gastric antrum. finally, targeted biopsy of the examined site was performed.

Eligibility criteria:
inclusion criteria: 1. male or female aged 18-80 ; 2. those fulfilling the criteria of gim according to the study by yuting guo et al were included. exclusion criteria: 1. patients younger than 18 years or older than 80 years; 2. finding of acute gi bleeding, gastrectomy or known upper gastrointestinal cancer; 3. unwillingness to participate in this study; 4. contraindications to cle, such as fluorescein allergy, hepatic or renal dysfunction, jaundice, pregnancy and/or breast feeding, coagulopathy.

Keywords: probe-based confocal laser endomicroscopy chronic atrophic antral gastritis microcirculatory dynamics
prospective observational cohort study for the durability of anti-viral therapy in patients with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: the aim of this study is to investigate the off-treatment sustained virological and biochemical response in chronic hepatitis b patients following the guideline by the asian pacific association for the study of the liver (apasl) in korea.

in the recommendation by the asian pacific association for the study of the liver(apasl), antiviral drug is recommended to stop when hbeag seroconversion has developed for more than 6 months among hbeag-positive patietns. for hbeag-negative patients, the apasl consensus recommended stopping anti-viral treatment when hbv dna remained undetectable for three separates occasion 6 months apart. nontheless, approximately 25% to 50% of the patients still develop hepatitis relapse after stopping anti-viral therapy even if these recommendations are followed. in this study, the investigators aimed to investigated the off-treatment sustained response in chronic hepatitis b parients following the stopping anti-viral treatment guideline in korea.

Eligibility criteria:
inclusion criteria: * more than 20 years old * chronic hepatitis b patients under anti-viral therapy 1. in hbeag-positive patient; if hbeag seroconversion with undetectable hbv dna is documented on two separate occasions at least 6 months 2. in hbeag-negative patient; if undetectable hbv dna has been documented on three separate occasions 6 months apart exclusion criteria: * patients who had chronic liver disease due to hemochromatosis, autoimmune hepatitis, drug-induced hepatitis, or thalassemia * patients who suffered from other chronic medical condition

Keywords: chronic hepatitis b nucleos(t)ide analogue antiviral treatment korea
cognitive correlates of substance abuse, part 2 - 16

Conditions: Amphetamine-Related Disorders

Summary: part ii: examine cognitive performance of stimulant abusers (methamphetamine and cocaine) during recovery by assessing their cognitive function at monthly intervals.

part ii: examine cognitive performance of stimulant abusers (methamphetamine and cocaine) during recovery by assessing their cognitive function at monthly intervals.

Eligibility criteria:
please contact site for information inclusion criteria: m/f. meet dsm-iv criteria for stimulant dependence. agree to conditions of the study and sign informed consent.
activation of the endocannabinoid system and cognition

Conditions: Post Traumatic Stress Disorder

Summary: recent data suggest that the cannabinoid-system is involved in stress regulation and posttraumatic stress disorder (ptsd). low endocannabinoid signaling has been found in ptsd patients and might even present a precondition to develop ptsd after trauma. the aim of the current project is to investigate the impact of an activation of the cannabinoid system with an exogenous cannabinoid (dronabinol, i.e., delta-9-tetrahydrocannabinol) on fear conditioning.

recent data suggest that the cannabinoid-system is involved in stress regulation and posttraumatic stress disorder (ptsd). low endocannabinoid signaling has been found in ptsd patients and might even present a precondition to develop ptsd after trauma. in consequence, increased endocannabinoid signaling during acquisition and consolidation of traumatic events might be a promising approach to prevent the development of ptsd. the aim of the current project is to investigate the impact of an activation of the cannabinoid system with an exogenous cannabinoid (dronabinol, i.e., delta-9-tetrahydrocannabinol) on tfear conditioning in patients with ptsd and healthy controls.

Eligibility criteria:
inclusion criteria: * ptsd criteria fullfilled (patients only) exclusion criteria: * all cases of physical illnesses and intake of medication (except oral contraceptives) (healthy controls only) will be excluded. * pregnant and lactating individuals will also be excluded. participants with a positive urinary cannabinoid test (cannabis 20 pipettier-drogenschnelltest (urin), diagnostik nord gmbh) will also be excluded. * psychiatric disorder according to dsm-5 (healthy controls only)
neurodevelopment in infants with complex congenital heart defects

Conditions: Complex Congenital Heart Defect

Summary: the primary goal of this study is to systematically describe early neurodevelopment using a complementary set of observational and neurophysiological measures that may predict cognitive and motor delays earlier than currently possible for infants with complex congenital heart disease (cchd).

the investigators' long-term goals are to develop a method of identifying infants likely to have adverse neurodevelopmental outcomes following neonatal treatment for cchd and to develop and test interventions that can be applied early in infancy. the necessary first step is to systematically describe early neurodevelopment using a complementary set of observational and neurophysiological measures that may predict cognitive and motor delays earlier than currently possible for infants with cchd. each measure provides unique information about development and will include (1) neuroimaging for brain maturity and brain injury, (2) hair and fingernails for cortisol and saliva for immune system function, (3) heart rate variability (hrv) for autonomic nervous system function (ans), (4) bayley scales of infant development (bsid-iii) for cognitive and motor function, (5) a naturalistic play session incorporating kicking, general movement analysis, or the test of infant motor performance (timp) for motor development, and (6) the mobile paradigm for learning, memory, and task-specific coordination. the investigators will look at types of relationships among these measures within each time point for description of development and across each time point for prediction of development. the investigators' core hypotheses are that infants with cchd will have measurable deficits in cognitive and motor development birth to \~ 6 months of age when compared with a healthy control group and that a typology developed from neurodevelopmental measures will reliably predict cognitive and motor delay in the first six months of life in infants with cchd.

Eligibility criteria:
inclusion criteria: * at least 36 weeks gestational age * diagnosed with a complex congenital heart defect * have at least one english-speaking adult family member exclusion criteria: * presence of co-existing, non-cardiac congenital anomalies * ongoing post-operative cardiac pacing

Keywords: complex congenital heart defect infants
salivary alkaline phosphatase as a biomarker for dental caries in a group of egyptian children with different growth rates: a descriptive cross-sectional study

Conditions: Dental Caries in Children

Summary: aim of the study: 1. assess the correlation between salivary alkaline phosphatase levels and dental caries. 2. assess the effect of growth of children on the levels of salivary alkaline phosphatase enzyme. 3. assess the effect of growth of children on caries experience and severity.


Eligibility criteria:
inclusion criteria: * children aged 6 to 8 years old. * children with and without previous dental visits. exclusion criteria: * children with any systemic or mental illness. * children whose parents refuse to sign the informed consent. * children who will not cooperate on participation
study to evaluate dnl747 in subjects with amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of dnl747 in subjects with amyotrophic lateral sclerosis in a cross-over design


Eligibility criteria:
key inclusion criteria (double-blind part): * women of non-childbearing potential and men, aged 21-80 years * willingness and ability to complete all aspects of the study; participant should be capable of completing assessments either alone or with help of a caregiver * diagnosis of laboratory-supported probable, probable, or definite (sporadic or familial) als according to the el escorial world federation of neurology revised research diagnostic criteria * less than 3 years since symptom onset * forced vital capacity (fvc) \>50% predicted measured within 30 days of screening * if subject is taking approved als treatments (riluzole and/or edaravone), doses must be stable for ≥2 months prior to screening and subject is expected to stay on a stable regimen throughout the study key exclusion criteria (double-blind part): * history of a clinically significant non-als neurologic disorder (other than frontal temporal lobe dementia), including, but not limited to, muscular dystrophy, spinal stenosis, peripheral neuropathy, inherited neuropathies, ad, parkinson's disease, lewy body dementia, vascular dementia, huntington's disease, epilepsy, stroke, multiple sclerosis, brain tumor, or brain infection or abscess * unstable or poorly controlled comorbid disease process of any organ system currently requiring active treatment or likely to require treatment adjustment during the study key inclusion criteria (open-label extension): * successful completion of both periods of the the double-blind, crossover part of the study * continued diagnosis of laboratory-supported probable, probable, or definite (sporadic or familial) als according to the el escorial world federation of neurology revised research diagnostic criteria key exclusion criteria (open-label extension): * presence of laboratory abnormalities, physical examination findings, or aes determined to be clinically significant by the investigator from the double-blind part of the study that have not resolved by the final follow-up visit as part of the double-blind study period * new diagnosis of clinically significant neurological disorder (other than frontal temporal lobe dementia)
cambridge anti-myopia trial: accommodation training and aberration control in myopia development

Conditions: Myopia

Summary: we have identified focussing problems related to myopia getting worse. our trial uses optical and orthoptic interventions that correct the focussing problems to see if this retards myopia progression.

myopia is a burgeoning health and social problem. currently there is no acceptable clinical treatment that prevents progression. this study is a double masked placebo controlled block randomized clinical trial of two interventions, to treat accommodative factors we have identified as being significantly correlated to myopia progression (rather than to the presence of myopia). we have shown that the interventions normalise the accommodative factors, and this trial examines the effect of these interventions on myopia progression.

Eligibility criteria:
inclusion criteria: * best corrected visual acuity of 6/5 in each eye * myopia in each meridian of at least 0.50 d * willingness to give consent * willingness to undertake any treatment option exclusion criteria: * history of systemic/ocular pathology * history of any ocular surgery * more than 10d of myopia * astigmatism more than 1.00 d

Keywords: aberration control accommodative facility accommodative response peripheral refraction accommodative convergence to accommodation ratio
ultrasound evaluation of superior mesenteric artery measurements in a healthy pediatric population

Conditions: Superior Mesenteric Artery Syndrome

Summary: multicenter, prospective, observational research project on children aged from 10 to 15 years old undergoing abdominal ultrasound examinations during routine clinical practice.

demographics data, clinical indications, ultrasound diagnosis, and ultrasound measurements will be recorded and stored on an database. ultrasound measurements will be analyzed to define the normal range of values of superior mesenteric artery (sma) angle and superior mesenteric artery - aorta (sma-a) distance in the pediatric population according to age, body mass index (bmi), and fat parameters.

Eligibility criteria:
inclusion criteria: * male and female children * age ranging from10 to 15 years, included * abdominal ultrasound examination to be performed for indications other than gastrointestinal evaluation * signed informed consent exclusion criteria: * presence of a disease that could distort the anatomy around the sma (e.g., abdominal mass, lymphadenopathy, severe scoliosis, free abdominal fluid) * oncologic patients at risk of neoplastic cachexia.
high cut-off hemodialysis in patients with advanced cardiac al amyloidosis and end stage renal disease

Conditions: Primary Amyloidosis of Light Chain Type

Summary: the aim of the study is to assess survival of patients with advanced cardiac al amyloidosis treated with high cut-off hemodialysis (hco-hd) combined with chemotherapy.

this will be a single-center phase ii open label trial. subjects with advanced cardiac al amyloidosis and end-stage renal disease will undergo hco-hd while receiving chemotherapy for their plasma cell dyscrasia according to the current standards of care. after giving written informed consent, the patients will be evaluated for eligibility. briefly, the subjects with a biopsy-proven diagnosis of al amyloidosis who are cardiac stage 3 based on nt-probnp (\> 332 ng/l) and ctni (\> 100 ng/l) and whose estimated glomerular filtration rate (egfr) is \< 15 ml/min per 1.73 m2 will be eligible for the study. patients with non-al (e.g. familial and senile) amyloidosis will be excluded, as well as subjects who have less than 100 mg/l circulating amyloidogenic flc. sixteen patients will be enrolled. the study includes 3 periods: screening, treatment followed by the end-of-treatment evaluation and follow-up. during dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac al amyloidosis. measurements of flc and cardiac biomarkers will be done before and after each dialysis session. high cutoff hd will be continued during the first chemotherapy cycle. after the first cycle the end-of-treatment evaluation will take place. follow-up evaluations will be performed after the end of each subsequent chemotherapy cycle and every 2 months after chemotherapy discontinuation for 1 year or until disease progression occurs.

Eligibility criteria:
inclusion criteria: * diagnosis of al amyloidosis. * age ≥ 18 years. * evidence of a monoclonal light chain in serum and/or urine by positive immunofixation and abnormal flc κ/λ ratio. * evidence of cardiac involvement at echocardiography (mean left ventricular wall thickness \> 12 mm in the absence of other causes). * cardiac stage iii (both nt-probnp \> 332 ng/l and ctni \> 100 ng/l). * estimated gfr \< 15 ml/min per 1.73 m2 or requiring dialysis. * nyha class iii or iv. * initiation of chemotherapy for al amyloidosis scheduled between day 3 and day 8 after first hco-hd session. exclusion criteria: * non-al (e.g. familial, senile) amyloidosis. * concomitant non-amyloid related clinically significant cardiac diseases. * involved (amyloidogenic) flc \< 100 mg/l. * inability to undergo chemotherapy for al amyloidosis. * uncontrolled infection. * inability to give informed consent. * previous or ongoing psychiatric illness (excluding reactive depression). * pregnant or nursing women.

Keywords: hco-hd survival cardiac biomarkers al amyloidosis light chain amyloidosis
improving muscle function in nutritionally at risk, elderly patients

Conditions: Muscle Weakness; ICU-acquired Weakness

Summary: the investigators propose to conduct a randomized, control trial of β-hydroxy-β-methylbutyrate (hmb) supplementation in elderly patients (≥65 years of age) with acute respiratory failure, who are identified at high risk for malnutrition by icu-specific nutritional risk scores. patients will receive either 3g of hmb daily, or control, daily until day 28 following randomization (even if discharged).the investigators will measure functional outcomes using standard, validated measures prior and after discharge.

the investigators propose to conduct a randomized, control trial of hmb supplementation in elderly patients (≥65 years of age) with acute respiratory failure, who are identified at high risk for malnutrition by icu-specific nutritional risk scores. patients will receive either 3g of hmb daily, or control, daily until day 28 following randomization (even if discharged).the investigators will measure functional outcomes using standard, validated measures prior and after discharge. the investigators hypothesize that this inexpensive nutrient, hmb, along with our supportive measures, reduces muscle loss, improves physical muscle function, and improves quality of life in the longer term following critical illness.

Eligibility criteria:
inclusion criteria: 1. patients age ≥65 years. 2. acute respiratory failure (arf, defined by expected mechanical ventilation for \> 72 hours from the point of screening) 3. elevated nutritional risk (nutric score\>5 - see below). exclusion criteria: 1. over 72 hours from icu admission. 2. not expected to survive another 48 hours 3. lack of commitment to full, aggressive care 4. patients who have an absolute contraindication to en (obstruction, perforation, high output fistula), 5. pregnant women 6. prisoners 7. known allergy to study nutrients 8. unable to walk prior to current illness.

Keywords: icu-acquired weakness
type 2 hepatorenal syndrome

Conditions: Safety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRS

Summary: various vasoconstrictors have shown promising results in the management of type 1 hepatorenal syndrome (hrs). however, there are very few studies on vasopressors in the management of type 2 hrs. terlipressin has been used commonly; however it is costly and not available in some countries. in the present study, the investigators evaluated safety and efficacy of terlipressin and noradrenaline in the treatment of type 2 hrs


Eligibility criteria:
inclusion criteria: 1. cirrhosis with ascites with serum creatinine more than 1.5 mg/dl and less than 2.5 mg/dl 2. absence of shock, fluid losses and treatment with nephrotoxic drug 3. no improvement in renal function following diuretic withdrawal and plasma volume expansion 4. no ultrasound evidence of renal parenchymal disease or obstructive uropathy 5.absence of proteinuria more than 500 mg/24 hour exclusion criteria: 1. patients with history of coronary artery disease 2. cardiomyopathy 3. ventricular arrhythmia 4. obstructive arterial disease of limbs -

Keywords: noradrenaline terlipressin type 2 hrs
effectiveness of education in relaxation surgeries

Conditions: Cerebral Palsy

Summary: the study will be carried out with volunteer patients who are followed up by the orthopedics and traumatology outpatient clinic of muğla training and research hospital and diagnosed with cerebral palsy and meet the study criteria. the evaluations will be performed in the orthopedics and traumatology outpatient clinic of muğla training and research hospital. this study was planned to investigate the effectiveness of multicomponent home activities and family child education against conventional postoperative practices in children with cp who underwent lower extremity tendon release surgery. objective functional status, spasticity levels, pain levels, kinesiophobia levels and gait quality of the patients will be evaluated.


Eligibility criteria:
inclusion criteria: * children with walking cp between the ages of 4-18 years who have undergone lower extremity orthopedic surgery and at least 2 months have passed (leaving the acute and subacute period behind) * gross motor function classification (gmfcs) level 1 (walks without restrictions), 2 (walks with restrictions) or 3 (walks using hand-held mobility aids) * understand simple commands * signing the consent form exclusion criteria: * circumstances that would interfere with conducting assessments or communicating * lack of cooperation during the study * presence of severe mental retardation * presence of botulinum toxin application in the last 6 months
the efficacy of targeted training on the postural control and gross motor function in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: the project aims to test the effectiveness and explore the possibility of performing a novel therapeutic approach, targeting to increase strength and coordination around the trunk, giving a more active and functional seating and head control in those children with cerebral palsy (cp) who are wheelchair users. the project will also try to determine the muscle physiological effect of treatment using indirect measures of strength in the spinal musculature.


Eligibility criteria:
inclusion criteria: * diagnosis of cp made by a neuro-pediatric physician experienced in assessment and diagnosis of cp * gmfcs level iii, iv and v, * the child cannot walk without assistance, * age 2-15 year, * no joint deformity or contracture around the "targeted" joint * not a candidate for surgery or other medical treatment that affects motor skills while participating in the project * trunk control problems. exclusion criteria: * uncontrolled epilepsy * surgery within 12 months of the study start * botulinum toxin within 2 months of study start * lack of personnel resources to treat the child at their school/kindergarten

Keywords: postural control targeted training gross motor function cerebral palsy